Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates in multiple myeloma

J R Berenson1

  • 1West Los Angeles Veterans Affairs Medical Center and the Jonsson Comprehensive Cancer Center, University of California, 90073, USA.

Cancer
|November 15, 1997
PubMed
Summary

Pamidronate significantly reduced skeletal complications in multiple myeloma patients receiving chemotherapy. This bisphosphonate therapy improved bone pain and overall well-being, demonstrating safety and tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.

Blood cancer journal·2021
Same author

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.

Leukemia·2014
Same author

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.

Leukemia·2012
Same author

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.

Leukemia·2011
Same author

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.

Oncogene·2006
Same author

Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.

Leukemia·2004

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Multiple myeloma frequently causes severe skeletal complications like osteolytic lesions and fractures.
  • Existing treatments have limitations in preventing or managing these bone-related issues.

Purpose of the Study:

  • To evaluate the efficacy of pamidronate in reducing skeletal complications in multiple myeloma patients undergoing chemotherapy.
  • To assess the impact of pamidronate on bone pain, analgesic use, and patient performance status.

Main Methods:

  • A large, randomized, double-blind, placebo-controlled trial involving Stage III multiple myeloma patients.
  • Patients received either pamidronate (90 mg) or placebo intravenously every 4 weeks for 21 cycles, alongside standard antimyeloma chemotherapy.

Main Results:

  • Pamidronate significantly decreased the incidence of skeletal complications compared to placebo.
  • Patients on pamidronate experienced reduced bone pain, lower analgesic requirements, and improved performance status.
  • While overall survival was similar, a subset of patients whose initial chemotherapy failed showed improved survival with pamidronate.

Conclusions:

  • Pamidronate is a safe and effective adjunctive therapy for reducing skeletal morbidity in multiple myeloma.
  • Pamidronate improves quality of life by alleviating bone pain and enhancing functional status in these patients.

Related Experiment Videos